KTTA supplier relationships: what investors need to know

Pasithea Therapeutics (NASDAQ: KTTA) is a clinical-stage biotechnology company developing PAS-004, an oral macrocyclic MEK inhibitor for rare CNS indications. The company currently monetizes through equity financings and partnership/placement transactions while advancing clinical programs that, if successful, would drive licensing or product revenue down the road. For investors and operators evaluating supplier risk, the relevant picture is one of outsourced development and manufacturing, concentrated service relationships, and capital markets dependency.

If you want a concise supplier-risk briefing linked to deal exposure and partner concentration, see our research hub: https://nullexposure.com/

What follows is a concise operational read on Pasithea’s contracting posture, followed by a line‑by‑line ledger of public relationships identified in coverage and filings.

How Pasithea runs development work and what that implies for suppliers

Pasithea conducts drug development almost entirely through third parties. Clinical operations, preclinical studies and manufacturing are outsourced to contract research organizations (CROs) and contract manufacturing organizations (CMOs). This operating model reduces fixed overhead but concentrates operational risk in a small set of external providers and short-term engagements.

Contracting posture: Evidence points to predominantly short‑term, fee‑for‑service contracts for preclinical and early clinical work rather than long-term, integrated supply agreements. Pasithea’s payments to a single preclinical vendor totaled roughly $0.3 million, consistent with episodic project billing rather than large multi-year retainers.
Concentration and criticality: The company acknowledges that the termination of key supplier or CMO relationships would be disruptive and directly harmful to development timelines, signaling high criticality even when spend is modest.
Geographic footprint and trial maturity: Clinical activity is bi‑regional with sites in the U.S. and Eastern Europe, indicating a mix of domestic and EMEA trial dependencies that require coordination across regulators and logistics.
Counterparty mix: The supplier base is a mix of institutional CMOs/CROs and individual consultants (e.g., a named consulting agreement paying quarterly fees), implying parallel use of specialized advisors alongside third‑party service firms.
Spend posture: Current disclosed spend bands are small (sub‑$1m per engagement in at least one preclinical contract), consistent with early‑stage cost profiles but potentially volatile if scale-up or rework is required.

These themes translate to operational leverage to external vendors, concentrated single‑point supplier risks, and financing sensitivity—all factors investors should price when valuing development timelines and dilution risk.

Explore supplier exposure and related intelligence at https://nullexposure.com/

Company-level constraints and named supplier signals

Pasithea used a short‑term contract model in preclinical work; one contract with PsychoGenics ran from April to September 2023 and total payments were approximately $0.3 million, illustrating episodic project spend and limited vendor tenure for some activities. This excerpt explicitly names PsychoGenics and demonstrates the short‑term contract type.
The company engages individual consultants under paid agreements; for example, the Steinman Consulting Agreement pays $25,000 per quarter for advisory services, a clear signal of reliance on paid individual expertise.
Clinical development is geographically split between U.S. and Eastern Europe sites for first‑in‑human dose escalation studies, signaling cross‑border operational dependencies.
Multiple disclosures characterize third‑party manufacturers and service providers as critical to Pasithea’s ability to continue development and to obtain regulatory approvals; the company explicitly warns that terminating CMO agreements would disrupt product development.
The company reports reliance on CMOs to procure materials and produce drug substance/product under cGMP, indicating functional dependence on suppliers for regulatory‑compliant output.
Spend exposure in at least one named contract is in the $100k–$1m band, consistent with preclinical/early clinical vendor engagements rather than large commercial manufacturing contracts.

Relationship ledger — every public relationship found in coverage

Nasdaq / IPO coverage (FY2021)

Pasithea planned to list on Nasdaq under the symbol KTTA as part of its public-market transition, a structural event that expanded the company’s access to capital and institutional counterparties. This was reported in Renaissance Capital’s IPO coverage in FY2021.

H.C. Wainwright & Co. — exclusive placement agent (FY2025 / FY2026)

H.C. Wainwright acted as the exclusive placement agent for Pasithea’s $60 million public offering, reflecting a direct capital-markets supplier relationship that underpins the company’s working capital and clinical funding. This role is documented in GlobeNewswire and Yahoo Finance press releases announcing the closing and pricing of the offering in late 2025 (FY2025) and referenced in FY2026 coverage.

Intellectia.ai / H.C. Wainwright mention (FY2026)

Market intelligence sources such as Intellectia.ai reiterated that H.C. Wainwright was the exclusive placement agent for the offering, confirming the bank’s central role in the company’s financing execution. The mention is captured in Intellectia.ai stock news coverage in FY2026.

EF Hutton — sole bookrunner on IPO (FY2021)

EF Hutton acted as the sole bookrunner on Pasithea’s IPO, a primary underwriting relationship that supported the company’s initial public offering and market entry. Renaissance Capital’s IPO reporting from FY2021 identifies EF Hutton’s role.

GlobeNewswire / corporate announcements and conference activity (FY2026)

Corporate press releases distributed via GlobeNewswire were used to publicize investor events and corporate milestones, including planned presentations at conferences and offering closings; QuiverQuant referenced a GlobeNewswire release for Pasithea’s presentation at the Oppenheimer Healthcare Life Sciences Conference in early 2026 (FY2026).

University of Alabama at Birmingham — clinical trial site activation (FY2025)

Pasithea activated a clinical trial site at the University of Alabama at Birmingham for its Phase 1/1b study of PAS‑004 in adult NF1 patients, indicating an operational relationship with an academic clinical center for patient dosing and data capture. This activation was announced via Investing News in FY2025.

GlobeNewswire press release on financing close (FY2025)

GlobeNewswire reported the closing of the $60 million public offering of common stock in early December 2025, formally documenting the completion of the placement for which H.C. Wainwright served as exclusive placement agent. The December 2, 2025 press release provides the financing detail.

Bottom line and investor actions

Pasithea relies on a compact ecosystem of placement agents, CROs/CMOs, academic trial sites, and paid consultants. Capital‑markets partners (H.C. Wainwright, EF Hutton) are structural to near‑term liquidity, while CMOs/CROs and clinical sites are operationally critical. The combination of small per‑contract spend and high criticality implies that a single supplier disruption or delayed financing could materially stretch timelines and create dilution pressure.

For investors conducting deeper counterparty due diligence, review supplier tenure, backup manufacturer capability, and clinical‑site enrollment pacing as the next steps. If you want to benchmark supplier concentration across small-cap biotech peers, start here: https://nullexposure.com/

If you’re evaluating counterparties for operational resilience or preparing engagement documentation, detailed supplier mapping and contract maturity analysis are the logical follow-ups—our platform consolidates exactly this kind of exposure intelligence: https://nullexposure.com/